MIGENIX releases CEO message No.22

    VANCOUVER and San Diego, CA, Feb. 15 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC:
MGIFF), a clinical-stage developer of drugs for infectious diseases, has
issued its 22nd CEO Message from Jim DeMesa, MD, President & CEO. Today's CEO
Message provides a discussion of the company's expected progress in 2008 and
into 2009, including:

    Omigard (prevention of catheter-related infections):
        -  Phase III results in H2/08
        -  NDA submission in H1/09
        -  Rest of world partnership

    Celgosivir (hepatitis C virus):
        -  Phase II viral kinetics study results (including 600mg) in Q3/08
        -  Partnership

    CLS001 (rosacea and other dermatologic conditions):
        -  Enter Phase III clinical development

    MX-2401 (serious bacterial infections):
        -  Further advancement through preclinical development (clinicals
           could begin in 2009)

    To obtain a copy of the complete CEO Message, please visit the MIGENIX
web site at www.migenix.com or contact Investor Relations at 1-800-665-1968,
Extension 233 (also available on SEDAR and EDGAR).

    About MIGENIX

    MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the area
of infectious diseases. The Company's clinical programs include drug
candidates for the treatment of chronic hepatitis C infections (Phase II and
preclinical), the prevention of catheter-related infections (Phase III) and
the treatment of dermatological diseases (Phase II). MIGENIX is headquartered
in Vancouver, British Columbia, Canada with US operations in San Diego,
California. Additional information can be found at www.migenix.com.

    "Jim DeMesa"
    James M. DeMesa, M.D.
    President & CEO


    This news release contains forward-looking statements within the meaning
of the United States Private Securities Litigation Reform Act of 1995, and
forward-looking information within the meaning of applicable securities laws
in Canada, (collectively referred to as "forward-looking statements").
Statements, other than statements of historical fact, are forward-looking
statements and include, without limitation, statements regarding our strategy,
future operations, timing and completion of clinical trials, prospects, plans
and objectives of management. By their nature, forward-looking statements
involve numerous assumptions, known and unknown risks and uncertainties, both
general and specific, that contribute to the possibility that the predictions,
forecasts, projections and other things contemplated by the forward-looking
statements will not occur.
    Although our management believes that the expectations represented by
such forward-looking statements are reasonable, there is significant risk that
the forward-looking statements may not be achieved, and the underlying
assumptions thereto will not prove to be accurate. Forward-looking statements
in this news release include, but are not limited to, statements concerning
our expectations for: Phase III OmigardTM trial results in the second half of
2008 and if the results of this trial are positive, a new drug application
(NDA) being submitted for OmigardTM in the first half of 2009; celgosivir
Phase II viral kinetic results in the third quarter 2008; CLS001 entering into
Phase III clinical development, partnerships; and other progress expected in
2008 and into 2009.
    With respect to the forward-looking statements contained in this news
release, we have made numerous assumptions regarding, among other things:
Cadence's ability to enroll sufficient patients to complete the OmigardTM
Phase III trial; the adequacy of the OmigardTM trial design to generate data
that are deemed sufficient by regulatory authorities to support potential
regulatory filings, including acceptance and approval of an NDA, for
OmigardTM; Cutanea Life Sciences' ability to manage, fund and advance CLS001
into Phase III; the adequacy of the CLS001 Phase II results for regulatory
authorities to support advancing to Phase III; our ability to manage licensing
opportunities and arrangements; our ability to initiate, fund and complete
non-clinical studies, clinical studies, manufacturing and all ancillary
activities within our expected timelines; and future expense levels being
within our current expectations.
    Actual results or events could differ materially from the plans,
intentions and expectations expressed or implied in any forward-looking
statements, including the underlying assumptions thereto, as a result of
numerous risks, uncertainties and other factors including: dependence on
corporate collaborations; potential delays; uncertainties related to early
stage of technology and product development; uncertainties as to the
requirement that a drug be found to be safe and effective after extensive
clinical trials and the possibility that the results of such trials, if
completed, will not establish the safety or efficacy of our products;
uncertainties as to future expense levels and the possibility of unanticipated
costs or expenses or cost overruns; the possibility that opportunities will
arise that require more cash than presently anticipated and other
uncertainties related to predictions of future cash requirements; and other
risks and uncertainties which may not be described herein. Certain of these
factors and other factors are described in detail in the Company's Annual
Information Form and Annual Report on Form 20-F for and other filings with the
Canadian securities regulatory authorities and the U.S. Securities & Exchange

    Forward-looking statements are based on our current expectations and
MIGENIX assumes no obligations to update such information to reflect later
events or developments.

    The Toronto Stock Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this release.

For further information:

For further information: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666
Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group,
Tel: (212) 825-3210, Theproteam@aol.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890